C-Reactive Protein (CRP) (77-82) peptide

C-Reactive Protein (CRP) (77-82) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

VGGSEI

H-Val-Gly-Gly-Ser-Glu-Ile-OH

6

97.7%

C₂₃H₄₀N₆O₁₀

560.61

130349-01-8

Synthetic

Powder

CRP peptide 77‑82 is a short human C‑reactive protein fragment that significantly inhibits FMLP‑induced neutrophil chemotaxis in vitro and reduces neutrophil infiltration (by up to 90%) and alveolar protein leakage (by up to 55%) in mouse models of acute lung inflammation in vivo, exerting anti‑inflammatory effects comparable to native CRP but requiring a higher dose.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Heuertz RM, Ahmed N, Webster RO. Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol. 1996 May 1;156(9):3412-7. PMID: 8617967.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.